Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — Q2 2025 Earnings Presentation
13 slides from Abcellera Biologics's earnings presentation, Aug 7, 2025
Slide 1: Q2 2025 Business Update
Q2 2025 BUSINESS UPDATE COPYRIGHT © ABCELLERA August 7, 2025
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including statements made These statements involve risks, uncertainties and other factors that may cause pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act actual results, levels of activity, perfor
Slide 3: 2025 Priorities
2025 PRIORITIES Completed transition into clinical-stage biotech and on track to complete key priorities. Q2 2025 Business Update Completion of platform ABCL635 Phase 1 clinical investments by the first Nominated trials initiated (June 2025) an additional half of the year ~$750M development in availa
Slide 4: Internal Pipeline & Programs: ABCL635
INTERNAL PIPELINE & PROGRAMS First participants dosed in Phase 1 clinical trial of ABCL635, a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes). Q2 2025 Business Update Target Neurokinin 3 receptor (NK3R) Status Target Type The Phase 1 clinical trial
Slide 5: Internal Pipeline & Programs: ABCL575 dosing
INTERNAL PIPELINE & PROGRAMS ABCL575 has a projected dosing interval of once every 6 months. The predicted human half-life is 67 days based on mouse pharmacokinetic (PK) data. Modeled exposure based on preclinical PK data* Q2 2025 Business Update 600 mg 300 mg *** loading dose maintenance doses 90%
Slide 6: Internal Pipeline & Programs
INTERNAL PIPELINE & PROGRAMS Advanced ABCL688, the second program from our GPCR / ion channel platform, into IND/CTA-enabling studies. MOLECULE TARGET THERAPEUTIC AREA STAGE Q2 2025 Business Update Discovery IND-Enabling Phase I Phase 2 Phase 3 ABCL635 NK3R Endocrinology & Women’s Health ABCL575 OX4
Slide 7: Financials Update
7 COPYRIGHT © ABCELLERA Q2 2025 Business Update FINANCIALS UPDATE Q2 2025
Slide 8: We have the capabilities and the capital to execute on our strategy
~$750M in available liquidity We have the to execute on our strategy* capabilities and Q2 2025 Business Update the capital to ~$580M in total cash, cash equivalents, & marketable securities* execute on our strategy. ~$170M in total available government funding* COPYRIGHT © ABCELLERA * As of June 30,
Slide 9: Continuing portfolio growth with first AbCellera-led programs entering clinic
Continuing portfolio growth with first AbCellera-led programs entering clinic. Cumulative # of Cumulative # of Notable Updates on PARTNER-INITIATED PROGRAM STARTS MOLECULES IN THE CLINIC MOLECULES IN THE CLINIC WITH DOWNSTREAMS Q2 2025 Business Update Partner-led AbCellera-led Molecule This Update AB
Slide 10: Operating expenses reflect R&D investments
Operating expenses reflect R&D investments. Revenue USD Operating Expenses USD MILESTONES RESEARCH & SALES & GENERAL & LICENSING DEVELOPMENT MARKETING ADMIN RESEARCH FEES Q2 2025 Business Update -$1.7M $40.9M $39.2M -$1.2M $20.2M $19.0M $17.1M $10.4M -$0.1M $7.3M $3.1M $3.0M COPYRIGHT © ABCELLERA $5.
Slide 11: Net loss of $35M; equivalent to ($0.12) per share
Net loss of $35M; equivalent to ($0.12) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC AND DILUTED Q2 2025 Business Update ($34.7M) ($0.12) ($36.9M) ($0.13) COPYRIGHT © ABCELLERA Q2 2024 Q2 2025 Q2 2024 Q2 2025 11
Slide 12: Approximately $580M in total cash, equivalents, and marketable securities
Approximately $580M in total cash, equivalents, and marketable securities. Cash Flows USD $653M $580M Q2 2025 Business Update $469M Marketable Securities $461M Marketable Securities $12M Marketable Securities (net) $156M $3M $1M ($36M) Other Cash & ($44M) $92M Equivalents ($24M) Cash & Equivalents C
Slide 13: Thank You
COPYRIGHT © ABCELLERA 13 Q2 2025 Business Update THANK YOU